Skye Bioscience, Inc.
SKYE
$1.81
-$0.01-0.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3,260.12% | -98.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -100.00% | 100.00% | |||
| Total Operating Expenses | 114.63% | -40.88% | |||
| Operating Income | -114.63% | 40.88% | |||
| Income Before Tax | -150.02% | 50.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -150.02% | 50.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -150.02% | 50.67% | |||
| EBIT | -114.63% | 40.88% | |||
| EBITDA | -113.94% | 41.46% | |||
| EPS Basic | -142.93% | 50.88% | |||
| Normalized Basic EPS | -115.26% | 45.06% | |||
| EPS Diluted | -142.93% | 50.88% | |||
| Normalized Diluted EPS | -115.26% | 45.06% | |||
| Average Basic Shares Outstanding | 2.96% | 0.39% | |||
| Average Diluted Shares Outstanding | 2.96% | 0.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||